Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

NCT05170724 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Remibrutinib

Sponsor

Novartis Pharmaceuticals